Randomized, double-blind, placebo-controlled, multi-center, sequential cohort study to evaluate the effect of SLV320 in addition to chronic furosemide treatment on renal function in subjects with congestive heart failure and impaired renal function.
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2016
At a glance
- Drugs SLV 320 (Primary)
- Indications Heart failure
- Focus Biomarker; Therapeutic Use
- Sponsors Abbott Healthcare Products
- 31 Aug 2018 Biomarkers information updated
- 25 Mar 2008 Status changed from suspended to discontinued.
- 15 Feb 2008 Status changed from recruiting to suspended, as reported in ClinicalTrials.gov.